Skip to content
    UHS
    Earnings call· Dec 2025(Q4 FY25)

    UNIVERSAL HEALTH SERVICES Q4 FY25 earnings call UHS

    Feb 26, 2026 Source

    Executive summary

    Universal Health Services Q4 FY25 — Strong Growth and Strategic Investments

    Universal Health Services concluded FY25 with robust financial performance, driven by strong revenue growth, effective expense management, and strategic investments in capacity expansion and technology. The company is actively expanding its inpatient and outpatient footprints across both acute care and behavioral health segments, leveraging AI for operational efficiency and clinical outcomes. While facing headwinds from health insurance exchange reductions and new California staffing regulations in FY26, management remains optimistic about core growth and margin expansion, supported by continued expense discipline and outpatient strategy.

    Highlights

    5

    • Q4 FY25 revenue grew 9%, adjusted EBITDA net of NCI increased 10%, and adjusted EPS increased 20% YoY.

    • Full-year FY25 revenue grew 10%, adjusted EBITDA net of NCI increased 15%, and adjusted EPS increased 31% YoY.

    • Acute care margins improved by 150 bps to 15.8% for FY25 due to reduced contract labor costs and strong supply chain management.

    • Significant share repurchase activity, acquiring 4.65 million shares for $899 million in FY25, with $1.425 billion authorization remaining.

    • Outpatient behavioral strategy progressing with 10 new '1,000 branches Wellness' centers opened in FY25 and at least 10 more planned for FY26.

    Concerns

    5

    • Q4 FY25 acute care volumes were flat, impacted by softness in the Las Vegas market due to lower respiratory case levels.

    • Cash flows in FY25 were impacted by a $50 million increase in receivables at de novo hospitals and $145 million related to timing of Medicaid supplemental payments.

    • Anticipated adverse pretax earnings impact of $75 million in FY26 due to reductions in health insurance exchanges, with volumes expected to decline 25-30%.

    • Expected negative pretax earnings impact of $35 million in FY26 from new California inpatient psychiatric hospital staffing regulations.

    • Q1 FY26 same-facility volume growth is likely to be below the 2-3% guidance range due to winter storms in Behavioral Health and Washington D.C. Acute Care segments.

    Guidance & targets

    14
    CategoryTargetConfidence
    Revenue
    $18.4 billion to $18.8 billion
    high materiality
    High
    Adjusted EBITDA net of NCI
    $2.64 billion to $2.79 billion
    high materiality
    High
    Adjusted Net Income Attributable to UHS per diluted share
    $22.64 to $24.52
    high materiality
    High
    Same-facility volume growth (both segments)
    2% to 3%
    medium materiality
    Medium
    Capital expenditures
    $950 million to $1.1 billion
    medium materiality
    High
    Acute Care pricing increase
    3% to 4%
    medium materiality
    High
    Behavioral pricing increase
    2% to 3%
    medium materiality
    Medium
    Adverse pretax earnings impact from health insurance exchanges
    $75 million
    high materiality
    High
    Negative pretax earnings impact from California staffing regulations (Behavioral)
    $35 million
    high materiality
    High
    Ongoing cost of California staffing regulations (Behavioral)
    $30 million
    medium materiality
    High
    Total net benefit from Medicaid supplemental payments
    $1.36 billion
    high materiality
    High
    Favorable pretax earnings impact from Cedar Hill improvements
    $50 million
    medium materiality
    High
    Favorable pretax earnings impact from other items
    $50 million
    medium materiality
    High
    Core growth from consolidated operations
    5%
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Acute Care Hospital
    Q4 2025 same-facility adjusted admissions were flat, impacted by softness in the Las Vegas market. Same-facility net revenues increased 6.9% (reported) and 5.2% (excluding insurance subsidiary). Operating expenses were well managed, with contract labor 20 bps lower year-over-year. Full year 2025 same-facility EBITDA margin improved by 150 bps.
    Same-facility adjusted admissions: flatSame-facility net revenues (ex-insurance subsidiary): 5.2% increaseSame-facility revenue per adjusted admission: 5.4% increaseSame-facility salaries, wages and benefits (ex-insurance subsidiary): 4.4% increaseSame-facility supply expense: 1.8% increaseSame-facility contract labor as % of revenue: 2.4%Same-facility segment EBITDA growth: 10.4%Same-facility segment EBITDA margin improvement: 50 bpsFull year Same-facility segment EBITDA margin (FY25): 15.8%Full year Same-facility segment EBITDA margin improvement (FY25): 150 bpsSame-facility acute care length of stay reduction (FY25): 2%
    		—6.9%—14.8%
    Behavioral Health
    Q4 2025 same-facility net revenues increased 7.2%, driven by increases in revenue per adjusted patient day and adjusted patient days. Expenses increased at a slightly higher pace due to headcount growth in certain markets to relieve staffing constraints. Margins were stable in 2025 compared to 2024.
    Same-facility revenue per adjusted patient day: 5.6% increaseSame-facility adjusted patient days: 1.5% increaseSegment headcount growth: 3.1%Total same-facility labor expense growth per adjusted day (U.S.): 7.3%Total segment EBITDA growth: 6.9%Full year Total segment EBITDA growth (FY25): 7.8%Outpatient services as % of segment revenue: 10%
    		—7.2%——

    Operational metrics

    13
    Adjusted Net Income Attributable to UHS per diluted share
    $5.88
    Q4 FY25

    After adjusting for items reflected on the supplemental schedule.

    Cash generated from operating activities
    $1.9 billionvs $2.1 billion in FY24
    FY25

    Impacted by $50 million increase in receivables at de novo hospitals and $145 million related to timing of Medicaid supplemental payments.

    Capital expenditures
    $1 billion
    FY25

    Reflecting investments in new facilities and expansions.

    Share repurchases
    $899 million
    FY25

    Including 1.46 million shares purchased during Q4 FY25.

    Repurchase authorization available
    $1.425 billion
    As of Dec 31, 2025

    Pursuant to stock buyback program.

    Available borrowing capacity
    $900 million
    As of Dec 31, 2025

    Aggregate available capacity.

    Acute Care segment adjusted admissions from exchanges
    6%
    FY25

    Represents the proportion of adjusted admissions from health insurance exchanges.

    Acute Care segment revenue from exchanges
    <5%
    FY25

    Represents the proportion of revenue from health insurance exchanges.

    Expected decline in exchange volumes
    25% to 30%
    FY26

    Based on CBO and other public projections.

    Expected shift of exchange volume to other coverage
    10% to 20%
    FY26

    Represents the portion of declining exchange volumes expected to find alternative coverage.

    Unapproved Florida Medicaid program potential benefit
    $45 million to $50 million
    Annual

    Expected benefit once approval is obtained; not included in current guidance.

    Ideal leverage ratio
    2x to 3x
    Ongoing

    Management's target range for net debt/EBITDA.

    Outpatient behavioral locations operated
    119
    Current

    Includes 10 new freestanding centers opened under '1,000 branches Wellness' brand during 2025.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trendsflat
    Same facility volumesflat
    Payer mix supplemental payments$1.36 billionUSD
    Adjusted EPS EBITDA leverage guidance$22.64 to $24.52USD

    Product announcements

    6
    ProductTypeDetails
    New Acute Care Hospitalslaunch
    Inpatient Expansions (Acute Care)expansion
    De Novo Hospital (Palm Beach Gardens, Florida)launch
    Behavioral De Novo Projectslaunch
    1,000 branches Wellness centerslaunch
    1,000 branches Wellness centersexpansion

    Deals & partnerships

    1
    Jefferson Health SystemJoint venture for a behavioral de novo project

    A joint venture project with the Jefferson Health System in Pennsylvania for one of the two behavioral de novo projects planned for 2026.

    Risks & headwinds

    8
    Softness in Las Vegas marketQ4 FY25

    Acute Care volumes flat in Q4 2025

    Mitigation: Assuming an uptick in 2026 based on stable employment trends and bullish convention bookings.

    Cash flow impact from receivables increaseFY25

    $50 million

    Cash flow impact from timing of Medicaid supplemental paymentsFY25

    $145 million

    Health insurance exchange reductionsFY26

    Adverse pretax earnings impact of $75 million in FY26; 25-30% decline in exchange volumes expected, with 10-20% shifting to self-pay/uninsured.

    Mitigation: Made best estimates, but will need more months to see how it sorts out.

    California inpatient psychiatric hospital staffing regulationsEffective June 1, 2026, and ongoing

    Negative pretax earnings impact of $35 million in FY26; ongoing costs of $30 million annually beyond 2026.

    Mitigation: Adjusting mix of licensed nursing staff, hiring more RNs, anticipating short-term census disruption, and working with payers for reimbursement offset.

    Q1 FY26 volume impact from winter stormsQ1 FY26

    Likely below 2-3% same-facility volume growth range for Q1 FY26

    Mitigation: Currently assessing impact in Behavioral Health and Washington D.C. Acute Care segments.

    Supply of subacute capacityOngoing

    Lack or dearth of capacity in many markets, leading to holding patients.

    Mitigation: Expectation that the marketplace for subacute capacity will expand over time.

    Medicaid work requirementsBeginning 2027

    Impact unknown, difficult to quantify.

    Mitigation: Picture expected to clarify as the year progresses.

    What to watch in Q1 FY26

    5

    Health insurance exchange volume decline

    Next quarter
    Current25-30% decline expected for FY26
    TargetActual impact on volumes and bad debt

    Why it matters

    The actual decline in exchange volumes and the shift to self-pay or uninsured could significantly impact revenue and profitability, especially in the Acute Care segment.

    But the truth is we're going to need a few more months to really see how this sorts out what the real loss in volume is, how many of these people who lose their exchange coverage can get other coverage, et cetera.

    Q&A highlights

    7

    What are the embedded pricing assumptions for 2026 in both segments, and how do AI applications translate into financial impact on operating performance and margins over time?

    Acute care pricing is expected to increase 3-4%, in line with historical averages and supported by acuity. Behavioral pricing is expected to increase 2-3%, a moderation from recent years but also in line with historical rates. AI applications are currently focused on administrative efficiencies (e.g., revenue cycle, claims appeals, coding) and post-discharge care (reducing readmissions), driving headcount reductions and improved outcomes. While difficult to precisely quantify, the opportunities are considered significant.

    “I think our initial efforts have really focused on administrative sort of efforts like within our revenue cycle management. I think Marc alluded to claims appeals and coding. And we've used that, I think, to great effectiveness.”

    asked by Albert Rice · answered by Steve Filton

    2 min read5 chapters

    Detailed Narrative

    01

    Growth Agenda and Capacity Expansion

    UHS has significantly expanded its capacity, opening two new acute care hospitals in the past two years. For 2026, the company plans three inpatient expansions totaling 178 licensed beds in Florida, California, and Nevada, alongside a new 156-bed de novo hospital in Palm Beach Gardens, Florida, opening in Q2. In the Behavioral segment, two de novo projects totaling 264 beds are planned for 2026, including a joint venture with Jefferson Health System in Pennsylvania. The outpatient behavioral strategy is also accelerating, with 10 new '1,000 branches Wellness' centers opened in 2025 and at least 10 more expected in 2026, aiming to diversify payer mix and service offerings.

    02

    Expense Management and Margin Improvement

    Acute care margins improved in 2025 due to reduced contract labor costs and strong supply chain management, with same-facility EBITDA margin improving by 150 basis points to 15.8% for the full year. Labor productivity also saw a 2% reduction in same-facility acute care length of stay. Behavioral segment margins remained stable in 2025, despite investments in staffing capacity to address labor constraints and support future volume growth. Management expects headcount growth in behavioral health to moderate in 2026, allowing for continued margin expansion.

    03

    Technology Adoption and AI Initiatives

    UHS is deploying AI and advanced technologies across operations and administrative functions. Agentic AI has been fully rolled out to improve post-discharge care and reduce readmissions. In 2026, the focus includes new patient safety technologies in behavioral health and AI deployment in acute care departments to enhance quality and outcomes. Administratively, AI-based solutions are improving documentation and streamlining claims appeals in acute care revenue cycle operations, with similar process improvements planned for behavioral health revenue cycle and referral/intake processes.

    04

    2026 Outlook and Key Assumptions

    The 2026 outlook includes several specific assumptions: an adverse pretax earnings impact of $75 million from health insurance exchange reductions, a negative pretax earnings impact of $35 million in the Behavioral segment due to new California staffing regulations, and a total net benefit of $1.36 billion from Medicaid supplemental payments. The company also anticipates $50 million of favorability from Cedar Hill improvements (offset by Palm Beach Gardens start-up) and another $50 million from discrete items📎 including a non-recurring📎 legal settlement and Behavioral M&A contributions.

    05

    Capital Allocation and Leverage Strategy

    UHS generated $1.9 billion in cash from operating activities in 2025 and spent $1 billion on capital expenditures, with 35% allocated to de novo hospitals and major expansions. The company repurchased 4.65 million shares for $899 million in 2025, with $1.425 billion remaining in authorization. Management maintains an ideal leverage ratio of 2x to 3x, emphasizing flexibility for potential M&A opportunities while continuing to view share repurchases as a compelling investment.

    AI-generated summary of the company’s earnings call. Not investment advice.